Search Result

Results for "

sEH Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Cholinesterase (ChE) (5) COX (3) Cytochrome P450 (1) Endogenous Metabolite (1) Epoxide Hydrolase (55) FAAH (2) FLAP (2) HDAC (2) Interleukin Related (1) Isotope-Labeled Compounds (1) Lipoxygenase (1) PGE synthase (1) PPAR (4) Prostaglandin Receptor (1) PROTACs (1) TNF Receptor (1)
By Research Areas:	Cancer (7) Cardiovascular Disease (22) Endocrinology (1) Infection (3) Inflammation/Immunology (31) Metabolic Disease (13) Neurological Disease (11)
Click Chemistry:	Azide (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148136

sEH inhibitor-7	Epoxide Hydrolase	Cardiovascular Disease Inflammation/Immunology
sEH inhibitor-7 (compound c-2) is an inhibitor of soluble epoxide hydrolase (sEH) with IC₅₀s of 0.15 μM (mouse sEH) and 6.2 μM (human sEH), respectively. soluble epoxide hydrolase (sEH) plays an important role in the metabolism of endogenous chemical mediators involved in the regulation of blood pressure and inflammation .

HY-155029

sEH inhibitor-16	Epoxide Hydrolase	Inflammation/Immunology
sEH inhibitor-16 is a soluble epoxide hydrolase (sEH) inhibitors with an IC₅₀ of 2 nM. sEH inhibitor-16 reduces the inflammatory damage in Cerulein (HY-A0190)-induced acute pancreatitis (AP) in mice and can be used for inflammation/immunology research .

HY-146643

sEH inhibitor-3	Epoxide Hydrolase	Neurological Disease
sEH inhibitor-3 (compound 35) is a potent and orally active soluble epoxide hydrolase (sEH) inhibitor with a K_i of 0.75 nM for human sEH .

HY-151617

sEH inhibitor-11	Epoxide Hydrolase	Inflammation/Immunology
sEH inhibitor-11 (compound 35) is a *sEH* inhibitor with an IC₅₀ value of 0.3 μM. sEH inhibitor-11 can be used for the research of inflammation .

HY-159121

sEH inhibitor-17	Epoxide Hydrolase	Neurological Disease Inflammation/Immunology
sEH inhibitor-17 (compound 4f) is an oral active soluble epoxide hydrolase (sEH) inhibitor with the IC₅₀ of 2.94 nM. sEH inhibitor-17 shows anti-inflammatory efficacy .

HY-151616

sEH inhibitor-10	Epoxide Hydrolase	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
sEH inhibitor-10 (Compound 37) is a selective soluble epoxide hydrolase (sEH) inhibitor (IC₅₀=0.5 μM). sEH inhibitor-10 maintains high cycloeicosatrienoic acid (EETs) levels by inhibiting *sEH, thereby reducing inflammation, regulating endothelial tone, improving mitochondrial function, and reducing oxidative stress. sEH* inhibitor-10 has good research potential in metabolic, renal and cardiovascular diseases .

HY-151619

sEH inhibitor-12	Epoxide Hydrolase	Inflammation/Immunology
sEH inhibitor-12 (compound 34) is a *sEH* inhibitor with an IC₅₀ value of 0.7 μM. sEH inhibitor-12 inhibits the 5-lipoxygenase-activating protein (FLAP)-mediated leukotriene (LT) biosynthesis with an IC₅₀ value of 2.9 μM. sEH inhibitor-12 can be used for the research of inflammation .

HY-148573

sEH inhibitor-14	Epoxide Hydrolase	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
sEH inhibitor-14 (compound 33) is a benzoxazolone-5-urea analogue. In addition, sEH inhibitor-14 is a soluble Epoxide Hydrolase (sEH) inhibitor (IC₅₀=0.39 nM) .

HY-143294

sEH inhibitor-2	Epoxide Hydrolase	Cardiovascular Disease
sEH inhibitor-2 (compound 5l) is an orally active (predicted percentage absorption: 71.2-88.4%) soluble epoxide hydrolase (sEH) inhibitor, with an IC₅₀ of 0.9 nM. sEH inhibitor-2 can maintain epoxyeicosatrienoic acids (EETs) serum level in high concentrations. sEH inhibitor-2 can be used in study of cardiovascular protection .

HY-148000

sEH inhibitor-6	Epoxide Hydrolase	Cardiovascular Disease Inflammation/Immunology
sEH inhibitor-6 (Compound 3g) is a soluble epoxide hydrolase (sEH) inhibitor with an IC₅₀ of 0.5 nM .

HY-173302

sEH inhibitor-20	Epoxide Hydrolase	Neurological Disease
sEH inhibitor-20 is an orally active and metabolically stable *sEH* inhibitor (IC₅₀: 0.2 nM). sEH inhibitor-20 has significant analgesic and anti-inflammatory activities and is expected to become a potential candidate compound for the study of neuropathic pain .

HY-151621

sEH inhibitor-13	Epoxide Hydrolase	Inflammation/Immunology
sEH inhibitor-13 (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor, with an IC₅₀ of 0.4 μM .

HY-147733

sEH inhibitor-5	Cholinesterase (ChE)	Inflammation/Immunology
sEH inhibitor-5 (compound D016) is a potent sEH (soluble epoxide hydrolase) inhibitor with an IC₅₀ value of 0.1 nM .

HY-120494

sEH inhibitor-1	Epoxide Hydrolase	Inflammation/Immunology
sEH inhibitor-1 (compound TCPU ) is a potent and oral active inhibitor of *sEH* (soluble epoxide hydrolase) with IC₅₀s of 0.4 and 5.3 nM in human and murine, respectively .

HY-170492

sEH inhibitor-19	Epoxide Hydrolase Interleukin Related TNF Receptor	Inflammation/Immunology
sEH inhibitor-19 (Compound (R)-14i) is an orally active inhibitor for soluble epoxide hydrolase (sEH) with an IC₅₀ of 1.2 nM. sEH inhibitor-19 inhibits the expression of TNF-α and IL-6, exhibits anti-inflammatory activity in mouse acute pancreatitis or Carrageenan (HY-125474)-induced edema models .

HY-147732

sEH inhibitor-4	Epoxide Hydrolase	Inflammation/Immunology
Intensive structural modification resulted in the identification of compound B15 as an effective sEH inhibitor with a value of 0.03 ± 0.01 nm, and the presence of soluble epoxide hydrolase (SEH) can reduce inflammation and pain.

HY-101294

TPPU Maximum Cited Publications 10 Publications Verification	Epoxide Hydrolase	Inflammation/Immunology
TPPU is a soluble epoxide hydrolase (sEH) inhibitor with IC₅₀ values of 37 and 3.7 nM for monkey and human sEH, respectively.

HY-123759

sEH-IN-12	Endogenous Metabolite	Others
sEH-IN-12 is a potent soluble epoxide hydrolase (sEH) inhibitor with the property of inhibiting sEH activity. sEH-IN-12 was successfully used in the construction and selection of small molecule libraries, showing excellent biological activity. The development of sEH-IN-12 provides a new tool for drug discovery targeting sEH .

HY-156329

sEH/FLAP-IN-1	Epoxide Hydrolase FLAP	Inflammation/Immunology
sEH/FLAP-IN-1 (Compound 46A) is a *sEH/FLAP* inhibitor. sEH/FLAP-IN-1 inhibits 5-LOX product formation in SACM-stimulated PBMCs (EC₅₀: 11 nM). sEH/FLAP-IN-1 inhibit sEH (EC₅₀: 18 nM) and thromboxane production. sEH/FLAP-IN-1 can be used for research of inflammatory diseases .

HY-160676

sEH-IN-1	Epoxide Hydrolase	Cardiovascular Disease Metabolic Disease Inflammation/Immunology
sEH-IN-1 (example 67) is a soluble epoxide hydrolase (sEH) inhibitor. sEH-IN-1 can be used in the research of sEH-mediated diseases such as hypertension, cardiovascular disease, inflammation, diabetes, and so on .

HY-159171

sEH/HDAC6-IN-2	Epoxide Hydrolase HDAC	Neurological Disease Inflammation/Immunology
sEH/HDAC6-IN-2 is a potent dual soluble epoxide hydrolase (sEH) and HDAC6 inhibitor with IC₅₀s of 0.9 nM, 46.8 nM, and 8 nM for human sEH, mouse sEH, and HDAC6, respectively. sEH/HDAC6-IN-2 can be used for the study of inflammatory pain .

HY-163207

sEH/HDAC6-IN-1	Epoxide Hydrolase HDAC	Neurological Disease
sEH/HDAC6-IN-1 (compound M9) is a selective, orally active dual inhibitor for *sEH* and HDAC6, with IC₅₀s of 2 nM, 0.72 nM and 5 nM, for human sEH, murine sEH and HDAC6, respectively. sEH/HDAC6-IN-1 reveals analgesic and anti-inflammatory effects .

HY-145831

sEH/AChE-IN-1	Cholinesterase (ChE)	Neurological Disease Inflammation/Immunology
sEH/AChE-IN-1 (Compound 12a) is a dual inhibitor of the enzymes soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE). sEH/AChE-IN-1 provides cumulative effects against neuroinflammation and memory impairment. sEH/AChE-IN-1 has the potential for the research of Alzheimer's disease (AD) .

HY-19644

GSK2256294A 2 Publications Verification GSK 2256294	Epoxide Hydrolase	Cardiovascular Disease
GSK2256294A (GSK 2256294) is a selective and orally active inhibitor of soluble epoxide hydrolase (sEH). GSK2256294A inhibits recombinant human sEH, rat sEH orthologs and murine sEH orthologs with IC₅₀s of 27, 61 and 189 pM, respectively. GSK2256294A can be used for the research of chronic obstructive pulmonary disease (COPD) and cardiovascular disease .

HY-145832

sEH/AChE-IN-2	Cholinesterase (ChE)	Neurological Disease Inflammation/Immunology
sEH/AChE-IN-2 (Compound 12b) is a dual inhibitor of the enzymes soluble epoxide hydrolase (sEH) and acetylcholinesterase (AChE). sEH/AChE-IN-2 provides cumulative effects against neuroinflammation and memory impairment. sEH/AChE-IN-2 has the potential for the research of Alzheimer's disease (AD) .

HY-126326

SWE101	Epoxide Hydrolase	Metabolic Disease
SWE101 (compound 22 b) is a potent soluble epoxide hydrolase (sEH)-P inhibitor with IC₅₀s of 4 μM and 2.8 μM for human and rat sEH-P, respectively. SWE101 does not inhibit neither hydrolase nor phosphatase activity of the mouse sEH .

HY-113974

trans-AUCB 1 Publications Verification t-AUCB	Epoxide Hydrolase	Cancer
trans-AUCB (t-AUCB) is a potent, orally active and selective soluble epoxide hydrolase (sEH) inhibitor with IC₅₀s of 1.3 nM, 8 nM, 8 nM for hsEH, mouse sEH and rat sEH, respectively. trans-AUCB has anti-glioma activity .

HY-144738

Dual FAAH/sEH-IN-1	Epoxide Hydrolase FAAH	Inflammation/Immunology
Dual FAAH/sEH-IN-1 (compound 3) is a high affinity dual *sEH* (soluble epoxide hydrolase) and FAAH (fatty acid amide hydrolase) inhibitor, with IC₅₀ values of 9.6 and 7 nM, respectively. Dual FAAH/sEH-IN-1 shows antinociception against the inflammatory phase .

HY-170610

mPGES-1/sEH-IN-1	Epoxide Hydrolase Prostaglandin Receptor	Inflammation/Immunology Cancer
mPGES-1/sEH-IN-1 (compound 1f) is an inhibitor of sEH with IC₅₀ value of 5 μM. mPGES-1/sEH-IN-1 shows antitumor activity with IC₅₀ value of 25 µM via inhibts mPGES‐1 .

HY-121538

CUDA	Epoxide Hydrolase PPAR	Cardiovascular Disease
CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC₅₀s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively . CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease .

HY-111151

AR-9281 APAU	Epoxide Hydrolase	Infection Cardiovascular Disease Metabolic Disease
AR9281 (APAU) is a potent, selective and orally active soluble epoxide hydrolase (s-EH) inhibitor. AR-9281 can inhibits human sEH (HsEH) and murine sEH (MsEH) with IC₅₀ values of 13.8 nM and 1.7 nM, respectively. AR9281 can be used for the research of inflammation, hypertension and type 2 diabetes .

HY-146704

COX-2/sEH-IN-1	Epoxide Hydrolase COX	Cardiovascular Disease
COX-2/sEH-IN-1 (Compound 9c) is an orally active, dual COX-2 and *sEH* (soluble epoxide hydrolase) inhibitor with IC₅₀ values of 1.24 µM and 0.40 nM against COX-2 and sEH, respectively. COX-2/sEH-IN-1 shows improved anti-inflammatory activity and highly reduced cardiovascular risks .

HY-163401

Epoxykynin	Epoxide Hydrolase	Cancer
Epoxykynin is a potent epoxide hydrolase (sEH) inhibitor .

HY-121538A

CUDA disodium	Epoxide Hydrolase PPAR	Cardiovascular Disease
CUDA disodium is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC₅₀s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively . CUDA disodium selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA disodium may be valuable for the research of cardiovascular disease .

HY-159494

PROTAC sEH-degrader-1	PROTACs Epoxide Hydrolase	Metabolic Disease
sEH-degrader-1 (Compound 8) serves as an inhibitor for *sEH, with IC₅₀* values of 3.8 nM and 210 nM against hsEH and msEH respectively. sEH-degrader-1 can effectively degrade *sEH* in mouse liver and brown adipose tissue (Red: UC-1728 (HY-114266), black: linker (HY-W248248), Blue: Thalidomide-5-piperazine (HY-W834174)) .

HY-108570

AUDA 3 Publications Verification	Epoxide Hydrolase	Inflammation/Immunology
AUDA (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor with IC₅₀s of 18 and 69 nM for the mouse and human sEH, respectively . AUDA has anti-inflammatory activity .

HY-121538S

CUDA-d11	Isotope-Labeled Compounds Epoxide Hydrolase PPAR	Cardiovascular Disease
CUDA-d₁₁ is deuterium labeled CUDA (HY-121538). CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC₅₀s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively . CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease .

HY-159169

5-LOX/sEH-IN-1	COX Epoxide Hydrolase Lipoxygenase	Inflammation/Immunology
5-LOX/sEH-IN-1 (Compound 8o) is a dual *5-LOX/sEH-IN-1* inhibitor with cardioprotective effects, exhibiting IC₅₀ values of 3.05 μM and 2.20 nM respectively, and 5-LOX/sEH-IN-1 can also inhibit the activity of COX-2 (IC₅₀=10.50 μM). 5-LOX/sEH-IN-1 has analgesic and anti-inflammatory effects, while reducing ulcer pathogenicity, and can be used to develop anti-inflammatory agents with fewer gastrointestinal and cardiovascular side effects .

HY-111151R

AR-9281 (Standard)	Epoxide Hydrolase	Infection Cardiovascular Disease Metabolic Disease
AR-9281 (Standard) is the analytical standard of AR-9281. This product is intended for research and analytical applications. AR9281 (APAU) is a potent, selective and orally active soluble epoxide hydrolase (s-EH) inhibitor. AR-9281 can inhibits human sEH (HsEH) and murine sEH (MsEH) with IC50 values of 13.8 nM and 1.7 nM, respectively. AR9281 can be used for the research of inflammation, hypertension and type 2 diabetes .

HY-162120

FZQ-21	Epoxide Hydrolase	Infection
FZQ-21 (Compound 70P) is a soluble epoxide hydrolase (sEH) inhibitor, with an IC₅₀ of 4 nM. FZQ-21 exhibits equal IC₅₀ (1.5 nM) on inhibiting human sEH as EC5026 (HY-135653) (1.7 nM). FZQ-21 can be used for research of sepsis .

HY-108570R

AUDA (Standard)	Epoxide Hydrolase	Inflammation/Immunology
AUDA (Standard) is the analytical standard of AUDA. This product is intended for research and analytical applications. AUDA (compound 43) is a potent soluble epoxide hydrolase (sEH) inhibitor with IC50s of 18 and 69 nM for the mouse and human sEH, respectively . AUDA has anti-inflammatory activity .

HY-145833A

sEH/AChE-IN-4	Epoxide Hydrolase Cholinesterase (ChE)	Neurological Disease Cancer
sEH/AChE-IN-4 (compound (+)-15) is a potent and BBB-penetrated dual inhibitor of *sEH* (soluble epoxide hydrolase) and AChE (acetylcholinesterase), with IC₅₀ values of 3.1 nM (hsEH), 1660 nM (hAChE), 179 nM (hBChE, human butyrylcholinesterase), 14.5 nM (msEH), and 102 nM (mAChE), respectively .

HY-114266

UC-1728 t-TUCB	Epoxide Hydrolase	Cardiovascular Disease Inflammation/Immunology
UC-1728 is a potent rabbit soluble epoxide hydrolase *(sEH)* inhibitor, with an IC₅₀ of 2 nM on rabbit liver.

HY-173568

DJ-89	Epoxide Hydrolase	Inflammation/Immunology
DJ-89 (Compound 77) is a potent soluble epoxide hydrolase (sEH) inhibitor with an IC₅₀ value of 0.51 nM . DJ-89 inhibits sEH from hydrolyzing epoxyeicosatrienoic acids (EETs), reducing the production of pro-inflammatory substances. DJ-89 is promising for research of acute and chronic inflammatory diseases (such as rheumatoid arthritis) .

HY-145833

sEH/AChE-IN-3	Epoxide Hydrolase Cholinesterase (ChE)	Neurological Disease Cancer
sEH/AChE-IN-3 (compound (−)-15) is a potent and BBB-penetrated dual inhibitor of *sEH* (soluble epoxide hydrolase) and AChE (acetylcholinesterase), with IC₅₀ values of 0.4 nM (hsEH), 1.94 nM (hAChE), 615 (hBChE, human butyrylcholinesterase), 4.3 nM (msEH), and 2.61 nM (mAChE), respectively .

HY-122591

PTUPB 1 Publications Verification	COX	Metabolic Disease Cancer
PTUPB is a potent and dual *sEH* and COX-2 enzymes inhibitor with IC₅₀ of 0.9 nM and 1.26 μM, respectively .

HY-124063

BI-1935	Epoxide Hydrolase	Cardiovascular Disease
BI-1935 is a potent soluble epoxide hydrolase (sEH) inhibitor. BI-1935 can be used for the research of cardiovascular disease .

HY-N15525

Arabinothalictoside	Epoxide Hydrolase	Cardiovascular Disease Metabolic Disease
Arabinothalictoside is found in A. squamosa L. Arabinothalictoside is a *sEH* inhibitor (IC₅₀: 47.1 µM). Arabinothalictoside can be used in the research of cardiovascular and urinary diseases .

HY-128171

Diflapolin 1 Publications Verification	FLAP Epoxide Hydrolase	Inflammation/Immunology
Diflapolin is a highly active dual 5-lipoxygenase-activating protein (FLAP)/soluble epoxide hydrolase *(sEH)* inhibitor with marked anti-inflammatory efficacy and high target selectivity. Diflapolin inhibits 5-LOX product formation in intact human monocytes and neutrophils with IC₅₀s?of? 30 and 170?nM, respectively, and suppressed the activity of isolated sEH (IC₅₀=20?nM) .

HY-138051

TUPS	Cytochrome P450	Cancer
TUPS can inhibit the gene expression of epoxide hydrolase (sEH) and cytochrome P450 (CYP). TUPS can be used in cardiovascular disease-related research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N15525

Arabinothalictoside	Structural Classification Annona squamosa L. Source classification Plants Annonaceae Saccharides Monosaccharides	Epoxide Hydrolase
Arabinothalictoside is found in A. squamosa L. Arabinothalictoside is a *sEH* inhibitor (IC₅₀: 47.1 µM). Arabinothalictoside can be used in the research of cardiovascular and urinary diseases .

HY-N15524

Thalictoside	Structural Classification Annona squamosa L. Source classification Plants Annonaceae Saccharides Monosaccharides	Epoxide Hydrolase
Thalictoside is found in A. squamosa L. Thalictoside is a *sEH* inhibitor (IC₅₀: 20.2 µM). Thalictoside exerts anti-osteoporotic effects through an estrogen-like mechanism. Thalictoside can be used in the research of cardiovascular and urinary diseases .

HY-N15521

Moracin M 3’-O-β-glucopyranoside	Structural Classification Source classification Phenols Polyphenols Plants Moraceae Morus alba Linn.	Epoxide Hydrolase
Moracin M 3’-O-β-glucopyranoside is found in Morus alba. Moracin M 3’-O-β-glucopyranoside is a *sEH* inhibitor (IC₅₀: 7.7 µM). Moracin M 3’-O-β-glucopyranoside exhibits anti-inflammatory activity .

Cat. No.	Product Name	Chemical Structure

HY-121538S

CUDA-d11
CUDA-d₁₁ is deuterium labeled CUDA (HY-121538). CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC₅₀s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively . CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease .

Cat. No.	Product Name		Classification

HY-159169

5-LOX/sEH-IN-1		Azide
5-LOX/sEH-IN-1 (Compound 8o) is a dual *5-LOX/sEH-IN-1* inhibitor with cardioprotective effects, exhibiting IC₅₀ values of 3.05 μM and 2.20 nM respectively, and 5-LOX/sEH-IN-1 can also inhibit the activity of COX-2 (IC₅₀=10.50 μM). 5-LOX/sEH-IN-1 has analgesic and anti-inflammatory effects, while reducing ulcer pathogenicity, and can be used to develop anti-inflammatory agents with fewer gastrointestinal and cardiovascular side effects .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

sEH Inhibitor

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products